2 cases dysgerminoma with micrometastasis in lymph nodes

Valdespino VE*, Montenegro YB, Hernandjez MR, Cordova GM, Mejia JL and Gomez VV

Gynecological and obstetrician hospital, “Luis Castelazo Ayala” Mexico City, Mexico

Abstract

We reported 2 cases of micrometastasis in dysgerminoma, specify incidence of micrometastasis is unknown. Many times when micrometastasis is reported, the variability is constant, those are reported in nodal sentinel dissection, or systematic lymphadenectomy, or with immunohistochemistry. We use the definition of micrometastasis agree with AJCC. (American Joint Committee on Cancer). We show 2 patients with retroperitoneal nodal micrometastasis and dysgerminoma; omentectomy, cytology, was performed and this resulted negative to metastasis. They received chemotherapy (4 times BEP) with good tolerance; both are alive without symptoms. We encourage sparing surgery for endocrine and reproductive function always. Nowadays micrometastasis is an advice to adjuvant treatment, but maybe with more reports, we can improve over medical care, perhaps target therapy, vigilance or use a low dose of chemotherapy. We need more reports on this subject. Over symptoms. We encourage sparing surgery for endocrinal and reproductive function always. Nowadays micrometastasis is an advice to adjuvant treatment, but maybe

Introduction

Ovarian dysgerminomas are infrequent and account for only about 2% of all malignant ovarian neoplasm [1]. They are female analogous to male seminoma and most commonly arise in adolescents and young women [2]. Seventy-five percent of women with dysgerminoma present with stage I at diagnosis and bilateral ovarian involvement occur in 10–15% [3]. Lymph node metastasis found in 28% of patients with ovarian dysgerminoma and was an independent predictor of poor survival [4]. On germinal ovarian cancer, dysgerminoma is most frequently related with nodal metastasis.

Dysgerminoma appears similar to; 80% to 90% are unilateral and grossly appear as tan-colored, lobulated, firm mass. It is composed of undifferentiated germ cells and large vesicular cells dispersed in sheets or cords interspersed by scant fibrous stroma, with a variable degree of atypia. Mature lymphocytes and occasional granulomas infiltrate the fibrous stroma. These malignant cells usually express CD117, OCT3, and OCT4 [5].

More than germinative malignant tumors 90% developed in gonads, and 10% are extragonadal, they are growing in retropertioneal, mediastinal or central nervous system [6].

Dysgerminoma has an excellent response to chemotherapy, those that have extended beyond the ovary can often be cured, with overall survival of greater than 80%. In treating dysgerminoma, surgery is not only therapeutic but also required for diagnosis and staging, with a scope of procedure dependent on intraoperative findings and patient’s desire whether or not she wants to maintain fertility or avoid exogenous estrogen [7,8].

Ovarian dysgerminoma is highly sensitive to platinum-based chemotherapy [9,10]. Adjuvant chemotherapy was associated with significant improvement in DFS (disease free survival) (HR, 0.09; 95% CI, 0.01–0.84; P = 0.034). The benefit and the risk of aggressive cytoreductive surgery for metastatic disease must be carefully weighed for this tumor. Even leaving residual disease after cytoreductive surgery in patients with advanced stage, they will have a long-term outcome with modern cisplatin-based adjuvant chemotherapy [10,11].

Cases

In ower hospital, micrometastasis is establish like a cluster from 0.2 mm to 2 mm malignant cells in nodal metastasis [12]. We systematically performed lymphadenectomy paraaortic and pelvic in ovarian cancer or nodal sentinel biopsy with blue dye (and standing surgery). We show 2 cases with micrometastasis in a services of gynecology oncology.

Case 1

Female patient 22 years old, no cancer family history, bachelor scholarship, no surgeries, no chronic disease. No pregnancy, no contraceptive method. She beginning 6 months before to the first appointment in gynecology oncology, with abdominal perimeter growing and menstrual bleeding pain. Laboratories result Ca125 117, AFP 0.99; DHL 889. Ultrasound with tumor irregular 23.6 x 19.7 x 19.1 cm.

We performed a surgery with transoperatory evaluation of tumor. The result was dysgerminoma; we used blue dye with retropertoneal sentinel node dissection. Dysgerminoma with micrometastasis in retropertoneal node dissection, one node with micrometastasis, 16 retropertoneal nodes were the total resected, and 14 pelvis nodes without metastases.

*Correspondence to: Valdespino VE, Gynecological and obstetrician hospital, “Luis Castelazo Ayala”, Mexico, Tel: +525573678619; E-mail edvaldespinocg@yahoo.com

Key words: micrometastasis, dysgerminoma, nodal retroperitoneal metastasis

Received: December 05, 2018; Accepted: December 20, 2018; Published: January 05, 2019
Case 2

Female patient 26 years old, a grandmother with colon cancer, bachelor not ended, the patient do not specify a time, no pregnancy story, no anticonception method. She develope cronic abdominal pain 4-5 months before to get medical attention, medical exploration shows us a tumor 10 cm in pelvis-abdomen. Ultrasound reported ovarian tumor 97 x 77 mm, mixed but solid in the majority. Laboratoris result DHL 1049, betaHGC 18. Transoperatory reported dysgerminoma, on tumor; transoperatory sentinel nodal disecction, do not report tumor (with blue dye) but in definitive result 1 nodal with micrometastasis. Also, pathologist reporte 19 retroperitoneal nodal without metastases and 15 pelvic nodes without metastases.

We are in a step of validation on sentinel node dissection. We used to send the sentinel nodal metastasis to transoperatory (and the pathologist give us a preliminar result) and 20 days later, pathologist report definitive, in both cases micrometastasis in one node. Also reported no metastasis in omentum. Ovarian tumor were in both cases dysgerminoma.

Pathology departmen cut 7 or 8 times each sentinel nodal; in a systematic lymphadenectomy just 1 time nodal is assess.

Both patients receive BEP bleomycin, etoposide and cisplatin 4 times, with good tolerance, they are alive without syntoms 24 months and 39 months, respectively (Figures 1-4).

Discussion

The main treatment for dysgerminoma includes surgery, and chemotherapy with optimal cytoreduction. The majority of patients (76.9%) in Husani's report underwent fertility-sparing surgery, and 44 (67.7%) received postoperative chemotherapy or radiotherapy. Only eight (12.3%) patients underwent complete surgical staging including omentectomy, cytology, and lymph node sampling/dissection [13]. Like Husaini ower oncology gynecology service encourage the fertility-sparing surgery but, systematically standing surgery is performed always: omentectomy, cytology, salpingo-oophorectomy and nodal evaluation with sentinel nodal dye and or systematic lymphadenectomy retroperitoneal and pelvic [14].

The germinates ovary tumors in our services, receives standing comprehensive surgery, in a different treatmetment than Vicus report, they do not perform the systematic standing in his report they only performed 4 standing operations [15].

Sentinel lymph node dissection is becoming increasingly popular in the management of gynecologic cancers.

In general, many autors classify lymph nodes involved with metastasis one of 3 categories based on the size of metastasis; ITC (isolated tumoral cells), 0.2 mm, micrometastasis, 0.2–2 mm and macrometastasis, 2 mm [12].
Regardless of our enhanced ability to detect nodal micrometastasis, the impact of their presence on prognosis remains unclear [3]. Probably the 9th edition of the AJCC staging manual will contain definitive data on this important subject (nodal micrometastasis) [16].

Low volume metastasis by producing VEGF (vascular endothelial growth factor) and other proangiogenic molecules, residual tumor cells can induce an "angiogenic switch" in avascular micrometastases that is necessary to convert them into macrometastases. Micrometastases might perhaps be more sensitive to VEGF depletion than large metastases, where VEGF is only one of the multiple factors perpetuating tumor angiogenesis. Anti-VEGF treatment could block tumor dissemination and inhibit the early growth of micrometastatic. This affirmation could be a normal treatment, but we need more clinical trials on micrometastasis [17].

First nodal level for ovarian metastasis is the retroperitoneal area, (paraaortic) when we practice the nodal sentinel dissection, always wait how many nodes dye and performed the resection, we can avoid the systematic dissection or continued with it. We send to transoperative evaluation and finished the surgery or continue systematic lymphadenectomy (we are in a process to validation).

We encourage the comprehensive surgery or sentinel node dissection in germinative ovarian cancer particularly in dysgerminoma, because only in this way that we can know all prognostic factors on primary cancer, nodal metastasis; and sometimes we can avoid chemotherapy and radiotherapy and those toxic effects on patients. The systematic retroperitoneal lymphadenectomy can remove micrometastasis or in those cases give us a positive chemotherapy indication treatment.

Micrometastasis most of the times are reported in a context of sentinel nodal dissection, but Suzuki and coworkers reported like us in comprehensive surgery but they used immunohistochemical staining. Reports of micrometastasis in ovarian cancer conditioned an adjuvant treatment [18].

We let the question open, and maybe in the future, we can answer, with many reports on micrometastasis in ovarian cancer. Nowadays if a patient has nodal metastases, they need chemotherapy in dysgerminoma [19]; but, if the patients have a systematic retroperitoneal node metastasis in malignant germ cell tumors of the ovary. Treatment of malignant germ cell tumors of the ovary with bleomycin, etoposide, and cisplatin: a Gynecologic Oncology Group Study. J Clin Oncol 25: 2792. [Crossref]

References

